Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
VENTOLIN ROTACAPS is a small-molecule inhalation capsule containing albuterol (salbutamol), a rapid-acting beta-2 agonist approved by GSK in 1988. It is used for the treatment of asthma and COPD, providing bronchodilation through airway smooth muscle relaxation. The product is administered via dry powder inhaler (rotahaler device) for acute symptom relief and maintenance therapy.
Product approaches loss of exclusivity with moderate competitive pressure (30/100), signaling preparation for generic competition and potential downsizing of brand-specific roles.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
VENTOLIN ROTACAPS offers limited career growth opportunities given approaching loss of exclusivity and zero linked job postings. Professionals assigned to this product should expect transition planning, focus on generic competition mitigation, and potential internal repositioning to GSK's growth-stage respiratory pipeline.
Worked on VENTOLIN ROTACAPS at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.